EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 30 / No 1 (Janvier 2014) Med Sci (Paris), 30 1 (2014) 15-18 References
Free Access
Issue
Med Sci (Paris)
Volume 30, Number 1, Janvier 2014
Page(s) 15 - 18
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20143001004
Published online 24 January 2014
  1. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013 ; 93 : 359–404. [CrossRef] [PubMed] [Google Scholar]
  2. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006 ; 444 : 860–867. [CrossRef] [PubMed] [Google Scholar]
  3. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010 ; 72 : 219–246. [Google Scholar]
  4. Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol 2009 ; 9 : 692–703. [CrossRef] [PubMed] [Google Scholar]
  5. Lonard DM, O’Malley BW. Nuclear receptor coregulators: modulators of pathology and therapeutic targets. Nat Rev Endocrinol 2012 ; 8 : 598–604. [CrossRef] [PubMed] [Google Scholar]
  6. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010 ; 10 : 365–376. [CrossRef] [PubMed] [Google Scholar]
  7. Mottis A, Mouchiroud L, Auwerx J. Emerging roles of the corepressors NCoR1 and SMRT in homeostasis. Genes Dev 2013 ; 27 : 819–835. [CrossRef] [PubMed] [Google Scholar]
  8. Li P, Fan W, Xu J, et al. Adipocyte NCoR knockout decreases PPARgamma phosphorylation and enhances PPARgamma activity and insulin sensitivity. Cell 2011 ; 147 : 815–826. [CrossRef] [PubMed] [Google Scholar]
  9. Venteclef N, Jakobsson T, Ehrlund A, et al. GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response. Genes Dev 2010 ; 24 : 381–395. [CrossRef] [PubMed] [Google Scholar]
  10. Toubal A, Clement K, Fan R, et al. SMRT-GPS2 corepressor pathway dysregulation coincides with obesity-linked adipocyte inflammation. J Clin Invest 2013 ; 123 : 362–379. [CrossRef] [PubMed] [Google Scholar]
  11. Calay ES, Hotamisligil GS. Turning off the inflammatory, but not the metabolic, flames. Nat Med 2013 ; 19 : 265–267. [CrossRef] [PubMed] [Google Scholar]
  12. Liao X, Sharma N, Kapadia F, et al. Kruppel-like factor 4 regulates macrophage polarization. J Clin Invest 2011 ; 121 : 2736–2749. [CrossRef] [PubMed] [Google Scholar]
  13. Stanley TL, Zanni MV, Johnsen S, et al. TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. J Clin Endocrinol Metab 2011 ; 96 : E146–E150. [CrossRef] [PubMed] [Google Scholar]
  14. Mack GS. Epigenetic cancer therapy makes headway. J Natl Cancer Inst 2006 ; 98 : 1443–1444. [CrossRef] [PubMed] [Google Scholar]
  15. Bantscheff M, Hopf C, Savitski MM, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011 ; 29 : 255–265. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.